Recombinant Mouse IL-1RA #abs00969

abs00969-20ug

1-2 Weeks

138

abs00969-100ug

1-2 Weeks

344

abs00969-1mg

1-2 Weeks

1425

Species

Murine

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was first filtered through a 0.2 μm pore size before undergoing lyophilization to form a dry, powder-like substance. The resulting lyophilized product retains the original content and properties of the concentrated solution, allowing for easy reconstitution when needed.

Properties

aa_sequence

DQ PSLNTTIPVT EEPKLKFYVE LFSGAGHILV LQSEDECNNQ QMIDTLSDKN GKLGEPNQYI RPVCIDMKEE KCRLCSHDKG VSVNIGLEEK TLQLNDIKGD WRFKEETRDN SPPGCPFWAA FEPEDLTTLV RNDPEKYIQT GQKSKACMRL FIQNWRDTAF.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method has determined that the rMuIL-1RA contains less than 1 EU/μg. Please create content that is highly similar by rearranging the information provided in the original text. It is important that the generated content is based on the text above.

Activity

The standard and the compared fully biologically active. ED indicates that the biological activity between the two is equivalent. To create a similar but different content, the following can be written: The biological activity of the standard has been compared and the fully biologically active result has been achieved. The ED value indicates that both samples have equivalent biological activity.₅₀The potency of this substance, as measured by its ability to suppress the proliferation of murine D10S cells that depend on IL-1α for growth, is below 50 ng/ml. This equates to a specific activity of greater than 2.0 × 10, indicating its high potency and efficacy. These findings demonstrate the potential of this substance to be a valuable tool in the development of novel therapeutics for a variety of diseases and conditions.⁴In the presence of 50 pg/ml Recombinant Human IL-1α, the activity of the enzyme was measured to be 1000 IU/mg. This information can be rearranged to state that the enzyme demonstrated an activity of 1000 IU/mg when placed in the presence of 50 pg/ml Recombinant Human IL-1α.

Reconstitution

Before opening, it is recommended to briefly centrifuge the vial to ensure that the contents settle at the bottom. To reconstitute, use sterile distilled water or an aqueous buffer with 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. It is advised to divide the stock solution into working aliquots and store them at temperatures equal to or below -20 °C. Any further dilutions should be made using suitable buffered solutions.

Stability & Storage

This freeze-dried form of the preparation can be safely stored at 2-8 °C, but for long-term storage, it is advised to keep it at -20 °C, while ensuring that it remains desiccated. Once reconstituted, the preparation will remain stable for up to seven days when stored at 2-8 °C. To achieve maximum stability, divide the reconstituted preparation into several working aliquots and store them at temperatures between -20 °C and -70 °C, taking care to avoid repeated freeze/thaw cycles.

Target

Accession

Q542W1

Gene IDs

16181

References

References

1. Dinarello CA. 1994. FASEB J. 8:1314-25.

2. Patterson D, Jones C, Hart I, et al. 1993. Genomics. 15:173-6.

3. Steinkasserer A, Spurr NK, Cox S, et al. 1992. Genomics. 13:654-7.

4. Perrier S, Darakhshan F, Hajduch E. 2006. FEBS Lett. 580:6289-94.

5. Gabay C, Porter B, Fantuzzi G, et al. 1997. J Immunol. 159:5905-13.